Published in J Cardiovasc Pharmacol on September 01, 1993
Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease. Br J Clin Pharmacol (2001) 0.95
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis. Br J Pharmacol (1996) 0.75
Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest (1999) 5.65
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation (1997) 3.58
Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis (2000) 3.09
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood (2000) 2.70
Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol (1997) 2.66
A lattice relaxation algorithm for three-dimensional Poisson-Nernst-Planck theory with application to ion transport through the gramicidin A channel. Biophys J (1999) 2.49
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood (2000) 2.48
Thrombolytic treatment. BMJ (1995) 2.37
Implicit and explicit memory for new associations in normal and amnesic subjects. J Exp Psychol Learn Mem Cogn (1985) 2.27
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet (1996) 2.20
Registry of Prospective Clinical Trials--Sixth Report. Thromb Haemost (1984) 2.16
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med (1997) 2.14
A novel biologically active seleno-organic compound--I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol (1984) 1.90
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol (2003) 1.86
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol (1992) 1.85
Thromboxane synthetase inhibition as antithrombotic strategy. Lancet (1981) 1.82
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood (2000) 1.81
Thrombolytic therapy with streptokinase using a standard dosage scheme. Br Med J (1966) 1.75
Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy (2006) 1.65
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
The information that amnesic patients do not forget. J Exp Psychol Learn Mem Cogn (1984) 1.60
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet (1985) 1.60
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med (1984) 1.57
Clinical application of inhibitors of fibrinolysis. Drugs (1985) 1.56
Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome. Crit Care Med (1998) 1.50
Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis. J Am Coll Cardiol (1990) 1.42
Intravascular coagulation in liver disease. Annu Rev Med (1974) 1.40
Post-infection transitory partial correction of thrombocytopenia in May-Hegglin anomaly. Am J Hematol (1994) 1.40
A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh (1968) 1.38
An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. AIDS (1996) 1.32
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant (2003) 1.31
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest (1983) 1.31
Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol (2000) 1.23
Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension (1990) 1.23
Sonography of the hand and foot in foreign body detection. J Ultrasound Med (1987) 1.23
Decreased flux through pyruvate dehydrogenase during calcium ion movements induced by vasopressin, alpha-adrenergic agonists and the ionophore A23187 in perfused rat liver. Biochem J (1983) 1.20
Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration. Eur J Clin Invest (1977) 1.19
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. J Am Coll Cardiol (1993) 1.18
Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension. Br Med J (1970) 1.14
Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene (2007) 1.14
Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost (1983) 1.13
In situ hybridization of immunoglobulin light chain mRNA in paraffin sections using biotinylated or hapten-labelled oligonucleotide probes. J Pathol (1990) 1.13
Are agents affecting platelet functions clinically useful? Am J Med (1976) 1.12
Double-blind experiments on the effect of a peanut extract on the bleeding incidence in 92 haemophiliacs. Br Med J (1967) 1.12
Acidic nonsteroid anti-inflammatory drugs accumulating in inflamed tissue. Experientia (1975) 1.11
Molecular biology of human plasminogen. II. Metabolism in physiological and some pathological conditions in man. Thromb Diath Haemorrh (1975) 1.11
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res (2011) 1.10
HIV-1 infection as a risk factor for leprosy; a case-control study in Tanzania. Int J Lepr Other Mycobact Dis (1993) 1.09
The difficulty of appraisal of streptokinase treatment of myocardial infarction. Angiologica (1971) 1.09
Systemic thrombolytic therapy of acute myocardial infarction? Circulation (1983) 1.08
An inhibitor of mitochondrial respiration which binds to cytochrome b and displaces quinone from the iron-sulfur protein of the cytochrome bc1 complex. J Biol Chem (1984) 1.08
Episodic spatial memory in adulthood. Psychol Aging (1993) 1.08
Immunochemical distinction between antiplasmin and alpha-antitrypsin. Thromb Res (1975) 1.07
Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. Br Med J (1970) 1.07
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia (2002) 1.07
Quantification of the alpha- and gamma-tocopherol metabolites 2,5,7, 8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman and 2,7, 8-trimethyl-2-(2'-carboxyethyl)-6-hydroxychroman in human serum. Anal Biochem (1999) 1.05
Benzalkonium chloride in nasal decongestive sprays has a long-lasting adverse effect on the nasal mucosa of healthy volunteers. Clin Exp Allergy (1995) 1.04
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int (2007) 1.03
Thrombolytic therapy in the eighties. Blood (1986) 1.03
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group. Circulation (1992) 1.03
Priming across modalities and priming across category levels: extending the domain of preserved function in amnesia. J Exp Psychol Learn Mem Cogn (1985) 1.02
Hepatic calcium efflux during cytochrome P-450-dependent drug oxidations at the endoplasmic reticulum in intact liver. Proc Natl Acad Sci U S A (1981) 1.02
Muscle blood flow in normal and hypertensive subjects. Influence of age, exercise, and body position. Am Heart J (1969) 1.01
Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest (2001) 1.00
The impact of 2D versus 3D quantitation of tumor bulk determination on current methods of assessing response to treatment. J Comput Assist Tomogr (1996) 1.00
Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. J Clin Pathol (2000) 0.99
Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. Circulation (1995) 0.98
Pharmacology of thrombolytic drugs. J Am Coll Cardiol (1986) 0.98
Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost (1994) 0.98
Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant (2005) 0.98
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost (1996) 0.97
Color-Word Stroop test performance across the adult life span. J Clin Exp Neuropsychol (1997) 0.97
Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost (1997) 0.96
Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation (1993) 0.96
Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy (2006) 0.96
Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol (2011) 0.96
RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer (1998) 0.95
Simulating amnesic symptoms in normal subjects. Science (1982) 0.95
Immunization of haemophiliacs against hepatitis B. A joint study between the haemophilia centers in Leuven, Belgium and Malmö, Sweden. Scand J Haematol Suppl (1984) 0.95
Aggregation of human platelets by bovine or human factor VIII: role of carbohydrate side chains. Nature (1973) 0.95
Platelet-aggregating activity in neuraminidase-treated human cryoprecipitates: its correlation with factor-VIII-related antigen. Br J Haematol (1974) 0.95
Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction. Eur Heart J (1985) 0.95
Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther (1985) 0.94
Investigations on the fibrinolytic system in liver cirrhosis. Acta Haematol (1968) 0.94
Hepatic thiol and glutathione efflux under the influence of vasopressin, phenylephrine and adrenaline. Biochem J (1985) 0.93
Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant (2010) 0.93
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation (1986) 0.93
Mechanisms of action of anti-inflammatory drugs. Gen Pharmacol (1976) 0.93
On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921). Thromb Res (1981) 0.93
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months. J Am Coll Cardiol (1986) 0.92
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol (1987) 0.91